Real-world Evidence Needs Careful Interpretation (Editorial)

No Thumbnail Available
File version
Author(s)
Nash, Peter
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2021
Size
File type(s)
Location
License
Abstract

The Janus kinase (JAK) inhibitors have proven to be popular across the globe for an increasing variety of autoimmune inflammatory disorders seen in rheumatology, dermatology, and gastroenterology1. In patients with rheumatoid arthritis (RA), market share is on the rise in many countries, with 4 or 5 JAK inhibitors available or under development, and most patient categories are comprehensively studied, such as methotrexate (MTX)-naïve, MTX-inadequate responders, biological disease-modifying antirheumatic drug (bDMARD)–inadequate responders, and monotherapy, in large randomized controlled trials (RCT) that have shown efficacy with a manageable safety profile.

Journal Title

Journal of Rheumatology

Conference Title
Book Title
Edition
Volume

48

Issue

1

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Clinical sciences

Immunology

Persistent link to this record
Citation

Nash, P, Real-world Evidence Needs Careful Interpretation., Journal of Rheumatology, 2021, 48 (1), pp. 1-2

Collections